Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

James F Howard

Showing results (101-110 of 117) with videos related to

Pageof 12
Sort By:
Mammalian Genome : Official Journal of the International Mammalian Genome Society|January 6, 2012
Canine models of Duchenne muscular dystrophy and their use in therapeutic strategiesJoe N Kornegay, Janet R Bogan, Daniel J Bogan, et al.
The Lancet. Neurology|April 14, 2023
Safety and efficacy of zilucoplan in patients with generalised myasthenia gravis (RAISE): a randomised, double-blind, placebo-controlled, phase 3 studyJames F Howard, Saskia Bresch, Angela Genge, et al.
Neurology|May 24, 2019
Randomized phase 2 study of FcRn antagonist efgartigimod in generalized myasthenia gravisJames F Howard, Vera Bril, Ted M Burns, et al.
Advanced Therapeutics|October 10, 2022
Classical Complement Pathway Inhibition in a "Human-On-A-Chip" Model of Autoimmune Demyelinating NeuropathiesJohn W Rumsey, Case Lorance, Max Jackson, et al.
Muscle & Nerve|June 3, 2020
Clinical features of LRP4/agrin-antibody-positive myasthenia gravis: A multicenter studyMichael H Rivner, Brandy M Quarles, Jin-Xiu Pan, et al.
Neurology|June 17, 2016
A randomized controlled trial of methotrexate for patients with generalized myasthenia gravisMamatha Pasnoor, Jianghua He, Laura Herbelin, et al.
Therapeutic Advances in Neurological Disorders|April 19, 2024
Long-term safety and efficacy of zilucoplan in patients with generalized myasthenia gravis: interim analysis of the RAISE-XT open-label extension studyJames F Howard, Saskia Bresch, Constantine Farmakidis, et al.
Muscle & Nerve|December 22, 2018
Thymectomy may not be associated with clinical improvement in MuSK myasthenia gravisKatherine M Clifford, Lisa D Hobson-Webb, Michael Benatar, et al.
Lancet (London, England)|April 24, 2026
Efficacy and safety of cemdisiran siRNA in myasthenia gravis (NIMBLE): a double-blind, randomised, placebo-controlled, phase 3 trialTuan Vu, Ali A Habib, Saiju Jacob, et al.
Nature Medicine|January 9, 2026
BCMA-directed mRNA CAR T cell therapy for myasthenia gravis: a randomized, double-blind, placebo-controlled phase 2b trialTuan Vu, Hacer Durmus, Michael Rivner, et al.
Pageof 12

Showing results (101-110 of 117) with videos related to

Sort By:
Pageof 12
Mammalian Genome : Official Journal of the International Mammalian Genome Society|January 6, 2012
Canine models of Duchenne muscular dystrophy and their use in therapeutic strategiesJoe N Kornegay, Janet R Bogan, Daniel J Bogan, et al.
The Lancet. Neurology|April 14, 2023
Safety and efficacy of zilucoplan in patients with generalised myasthenia gravis (RAISE): a randomised, double-blind, placebo-controlled, phase 3 studyJames F Howard, Saskia Bresch, Angela Genge, et al.
Neurology|May 24, 2019
Randomized phase 2 study of FcRn antagonist efgartigimod in generalized myasthenia gravisJames F Howard, Vera Bril, Ted M Burns, et al.
Advanced Therapeutics|October 10, 2022
Classical Complement Pathway Inhibition in a "Human-On-A-Chip" Model of Autoimmune Demyelinating NeuropathiesJohn W Rumsey, Case Lorance, Max Jackson, et al.
Muscle & Nerve|June 3, 2020
Clinical features of LRP4/agrin-antibody-positive myasthenia gravis: A multicenter studyMichael H Rivner, Brandy M Quarles, Jin-Xiu Pan, et al.
Neurology|June 17, 2016
A randomized controlled trial of methotrexate for patients with generalized myasthenia gravisMamatha Pasnoor, Jianghua He, Laura Herbelin, et al.
Therapeutic Advances in Neurological Disorders|April 19, 2024
Long-term safety and efficacy of zilucoplan in patients with generalized myasthenia gravis: interim analysis of the RAISE-XT open-label extension studyJames F Howard, Saskia Bresch, Constantine Farmakidis, et al.
Muscle & Nerve|December 22, 2018
Thymectomy may not be associated with clinical improvement in MuSK myasthenia gravisKatherine M Clifford, Lisa D Hobson-Webb, Michael Benatar, et al.
Lancet (London, England)|April 24, 2026
Efficacy and safety of cemdisiran siRNA in myasthenia gravis (NIMBLE): a double-blind, randomised, placebo-controlled, phase 3 trialTuan Vu, Ali A Habib, Saiju Jacob, et al.
Nature Medicine|January 9, 2026
BCMA-directed mRNA CAR T cell therapy for myasthenia gravis: a randomized, double-blind, placebo-controlled phase 2b trialTuan Vu, Hacer Durmus, Michael Rivner, et al.
Pageof 12